DSG2 and arrhythmogenic right ventricular cardiomyopathy: In terms of future perspectives, the assessment of anti-DSG2-ab in family members of ARVC patients and/or in carriers of genetic variants with negative phenotype could aid in determining the predictive role of such markers in the disease expressivity and progression.